Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and Align Technology

NEW YORK, December 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Becton, Dickinson and Company (NYSE: BDX), Sanofi SA (NYSE: SNY), GlaxoSmithKline plc (NYSE: GSK), Agilent Technologies Inc. (NYSE: A), and Align Technology Inc. (NASDAQ: ALGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Becton, Dickinson and Company Research Report

On November 26, 2013, Becton, Dickinson and Company (BD) reported that its Board of Directors declared a quarterly dividend of 54.5 cents per common share, indicating an increase of 5 cents per share, or approximately 10% QoQ. BD stated that the dividend is payable on December 31, 2013 to holders of record on December 10, 2013. The Company added that at the current rate, the annual dividend for FY 2014 would be $2.18 per share. Vincent A. Forlenza, Chairman, CEO and President, commented, "This is the forty-second consecutive fiscal year in which we have raised our dividend. This increase reflects our confidence in our long-term outlook, as well as our ongoing commitment of returning value to our shareholders." The Full Research Report on Becton, Dickinson and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



Sanofi SA Research Report

On November 25, 2013, Sanofi SA (Sanofi), along with Regeneron Pharmaceuticals, Inc. (Regeneron), announced that the Phase 2a study of dupilumab in asthma was selected as "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards, announced by Scrip- a leading pharmaceutical

industry publication. The Company informed that Dupilumab, which is being developed by Sanofi and Regeneron, is a fully-human monoclonal antibody that is in clinical development to cure asthma, atopic dermatitis, and nasal polyposis. George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories and Chief Scientific Officer, commented, "We appreciate the recognition by Scrip that dupilumab is one of the most exciting emerging clinical candidates in the industry." The Full Research Report on Sanofi SA - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



GlaxoSmithKline plc Research Report

On November 28, 2013, GlaxoSmithKline plc (GSK) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorization for a two-dose schedule in 9-14 year old girls for its cervical cancer vaccine, Cervarix™ [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant]. Thomas Breuer, Senior Vice President and Lead Physician, GSK Vaccines, commented, "We are delighted by the positive opinion issued by CHMP on a two-dose schedule for Cervarix. It represents another major milestone in our commitment to reducing the global burden of cervical cancer which remains high. Many countries are unable to implement national immunisation programmes in young adults with high coverage. A two-dose vaccine schedule has the potential to be easier to deliver than a three-dose schedule, thereby expanding the population that could benefit from protection." The Company added that a CHMP positive opinion is one of the last steps before marketing authorization is received from European Commission, but does not always result in marketing authorizations. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



Agilent Technologies Inc. Research Report

On November 22, 2013, Agilent Technologies Inc. (Agilent) announced that its Board of Directors has authorized a new share repurchase program, which will be effective once the Company's current $1 billion repurchase program concludes. The Company stated that the new repurchase program is intended to reduce or eliminate dilution which results from stock issuances under the Company's employee equity incentive programs for maintaining a share count of about 335 million diluted shares. Agilent added that the Board has also approved a 10% increase in the quarterly dividend to $0.132 per share, to be paid on January 22, 2014, to stockholders of record as of the close of business on December 31, 2013. The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



Align Technology Inc. Research Report

On December 2, 2013, Align Technology Inc. (Align) announced that it has extended its funding of the Align Research Award Program for the fifth straight year for universities in North America and for a fourth year for international universities. Align stated that it has also added two additional research awards to the international segment due to the rise in university research in programs outside of North America. The Company informed that the Align Research Award Program is an annually-funded program for promoting clinical and scientific research in clear aligner therapy. John Morton, Align's Director of Research and Technology, commented, "Study results from past awards have increased our understanding of treatment using clear aligners. In light of this success, we are excited to increase the number of research grants that may be funded this year." The Company informed that it has a total award pool of $325,000 for 2014. The Full Research Report on Align Technology Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:




  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



SOURCE Analysts' Corner